---
$id: https://graph.org.ai/products/commodity/51131730
$type: Product
source: UNSPSC
code: "51131730"
title: "Lotrafiban"
class: "51131700"
classTitle: "Thrombolytic drugs and platelet aggregation inhibitors"
family: "51130000"
familyTitle: "Hematolic drugs"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Lotrafiban

**UNSPSC Code**: 51131730
**Class**: [Thrombolytic drugs and platelet aggregation inhibitors](Thrombolytic drugs and platelet aggregation inhibitors.mdx)
**Family**: [Hematolic drugs](../Hematolic drugs.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes an antiplatelet agent with the molecular formula C23H32N4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KLQ306I83X, chemically known as 1h-1,4-benzodiazepine-2-acetic acid, 7-((4,4-bipiperidin)-1-ylcarbonyl)-2,3,4,5-tetrahydro-4-methyl-3-oxo-, (2s)- but generally known as lotrafiban, which bears US NIH Compound Identifier 80274. European Medicines Agency schedules Lotrafiban in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08601MIG. The term LOTRAFIBAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 No. 2 1999, List 40). LOTRAFIBAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lotrafiban under HS 29333999 and SITC 51574. As of Q4 2014, LOTRAFIBAN remains the US FDA Preferred Term for this commodity. Lotrafiban bears US NLM identifiers UMLS ID C0960422 and NCI Concept Code C81574. SMILES: O=C(N1CCC(C2CCNCC2)CC1)C1CC2C(NC(C(=O)N(C2)C)CC(=O)O)CC1.

